NewsCLINICALTRIALS.GOVMonday, April 13, 2026 · April 13, 2026
New recruiting trial: Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)
WHY IT MATTERS
New clinical trials expand access to investigational treatments for rare disease patients.
This study will collect, annotate, and sequence biospecimens (blood, tissue, urine, saliva and surgery drainage) from patients across different cancer types to detect molecular residual disease (MRD). Imaging scans and clinical data will also be gathered. This will allow for early cancer interceptio
Related news
ClinicalTrials.gov · April 14, 2026
New recruiting trial: Evaluation of Socio-professional Inclusion for Young Adults Aged 15-25 Living With a Rare Genetic Disability
Rare diseases are often synonymous with difficulties for sufferers, whether physical, mental or social. Patients sufferi…
ClinicalTrials.gov · February 20, 2026
New recruiting trial: FACE.S-4-KIDS : A Deep Phenotyping Database of Craniofacial Anomalies During Development With 4 Pilot Projects
FACE.S-4-KIDS is an ambitious database project addressing the scientific question of the variable expression of craniofa…
ClinicalTrials.gov · February 5, 2026
New recruiting trial: Genetic Aortic Diseases and Cardiovascular Complications. An Observational Survey of Risk Factors.
The aim of this observational study is to define the behavioural and cardiovascular risk factor profiles of patients wit…
ClinicalTrials.gov · January 29, 2026
New recruiting trial: Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors
Background:
Primary central nervous system (CNS) tumors grow in the brain and spinal cord. These tumors are rare, but t…